Molecular Partners AG(NASDAQ : MOLN)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
Health Technology » Biotechnology
|GILD||Gilead Sciences, Inc.||0.51%||64.80||1.0%||$543.24m|
|VRTX||Vertex Pharmaceuticals, Inc.||1.51%||273.73||1.9%||$497.98m|
|REGN||Regeneron Pharmaceuticals, Inc.||1.37%||692.80||2.6%||$444.80m|
|SNSS||Sunesis Pharmaceuticals, Inc.||2.38%||2.15||0.7%||$150.29m|
|EXAS||EXACT Sciences Corp.||7.96%||53.83||17.7%||$134.25m|
|TXG||10X Genomics, Inc.||11.91%||52.99||0.0%||$106.79m|
|BMRN||BioMarin Pharmaceutical, Inc.||2.68%||80.97||4.2%||$95.42m|
|CRSP||CRISPR Therapeutics AG||5.63%||58.34||0.6%||$85.42m|
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274 and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas PlÃ¼ckthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland.